Vincent Zucconi’s Post

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet Anita Scheuber and Hestia Therapeutics! Q: Tell us about your company and what you’re developing. What are you most excited about? A: At Hestia, we are developing the aNKor platform of tri-specific, tri-funtional immunocytokines that engage the adaptive AND innate immune system to very effectively attack cancer cells. Our approach is a targeted delivery of potent cytokines into the tumor microenvironment that is safer for patients compared to naked cytokines. Q: What advice do you have for other biotech companies just getting started? A: Surround yourself with a diverse group of people that bring industry relevant expertise to complement your own. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The Biotech hub in the Boston area remains strong, innovative and daring - it is just fantastic to learn through the MassBioDrive program that the immense resources, support and entrepreneurship still exists. It is truly inspiring and humbling to receive all that encouragement. Learn more about Hestia Therapeutics: https://hestiatx.com/ Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b

BGV (BioGeneration Ventures) announces portfolio company Kivu Bioscience's successful $92M Series A financing round. Kivu Bioscience is pushing boundaries in the field of antibody-drug conjugates (ADCs), leveraging the innovative Synaffix BV platform to enhance efficacy and reduce off-target toxicity. This significant funding will support the clinical development of multiple ADC programs, accelerating the company's path toward groundbreaking cancer therapies. Backed by Novo Holdings and joined by Gimv, Red Tree Venture Capital, HealthCap, and long-standing supporters M Ventures , BOM, and BGV, Kivu is positioned to make a substantial impact in ADC drug development under the expert leadership of Mohit Trikha, PhD. With decades of experience, Dr. Trikha and his world-class team are driving towards pivotal milestones that will reshape the treatment landscape. Click on the following link to learn more: https://lnkd.in/gexBkmbD #BioGenerationVentures #KivuBioscience #SeriesA #ADCs #Biotech #VentureCapital #LifeSciences #CancerResearch

We’re Making Headlines! We are beyond proud to see Synamics Therapeutics featured in MedWatch! In an exclusive interview, our CEO Violet Zahedi, M.D. discusses our recent investment news and shares our bold ambitions for the future. Read the full interview in English here: https://lnkd.in/dReseCFn #SynamicsTherapeutics #AI #CancerResearch #Investment #HealthcareInnovation #MedWatchInterview #Biotech #PrecisionMedicine

#fundingalert 💼Company: Avenzo Therapeutics 💰Funding: $150Million ⚡Round: Series A-1 👥Investors: INCE Capital, Delos Capital , Quan Capital, Deep Track Capital, Sofinnova Investments , and Sands Capital Avenzo Therapeutics was founded by Drs. Athena Countouriotis and Mohammad Hirmand in 2022, a clinical-stage biotechnology business. The company is developing and expanding a pipeline of possibly best-in-class cancer treatments that aim to stop the abnormal cell growth that is the main cause of many malignancies by targeting cell cycle control. With the money, the business hopes to expand its oncology pipeline, which is spearheaded by AVZO-021, a selective inhibitor of cyclin-dependent kinase 2 (CDK2) that may be the best in its class. Athena Countouriotis MD Mohammad Hirmand Paolo Tombesi Naresh Nayyar (PhD, RAC, MBA) Read more - https://lnkd.in/gF9zdfvq To share your startup story write us on - contact@startuprise.io #AvenzoTherapeutics #biotechstartup #oncology #bussiness #fundinhg #startup #fundingnews #startupnews #news #startuprise

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies https://lnkd.in/gtUqWBUp Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B to gather clinical data from its first two programs. It’s the 60th megaround of the year for private biotech companies, but Outpace didn’t originally have plans for a nine-figure raise. Investors kept piling in, though, CEO Marc Lajoie said in an interview. RA Capital Management led the round, which was announced Thursday. Bristol Myers Squibb, Artis Ventures and other existing backers from Outpace’s $30 million Series A from 2021 also joined the new funding. Qatar Investment Authority, Surveyor Capital, Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments and others invested in Outpace for the first time. The company is slated to enter the clinic next year with a mesothelin autologous CAR-T known as OPB-101, Lajoie said. In the past, Outpace looked at… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

🧪 Inspiration from Domestic Biomedical Startups 🧪   As we witness remarkable advancements in the biomedical field, I am particularly inspired by the promising young company Manebio, led by Anne Yagolovich. Manebio is at the forefront of developing therapeutic fusion proteins based on a modified human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), binding  to and activate death receptors 5 on tumor cells, triggering intracellular caspase reactions and inducing apoptosis, ultimately exerting powerful antitumor effects.   ✨ Recent in vivo studies by Manebio have yielded promising results in models of glioma and pancreatic cancer, highlighting the potential of their groundbreaking work. Adding to the optimism in our industry, the recent FDA approval of Aponermin, a recombinant circularly permuted TRAIL developed by Beijing Sunbio Biotech, marks a significant milestone.   As we continue to support and collaborate with startups like Manebio, we are reminded of the incredible potential that lies within our domestic innovations!   #BiomedicalInnovation #Startups #CancerResearch #TRAIL #Manebio #RPharm #Healthcare

Looking back on Venture Lab: Loma Therapeutics👀 Since we have opened our Venture Lab call once again, we want to share with you the reflections and learnings of the participating start-ups. Who better to enlist than our latest Venture House cohort, which has completed the Venture Lab program and is now embarking on our 18-month program designed to support product innovation and ecosystem growth, help projects mature, and attract further funding? First up is Loma Therapeutics, a start-up dedicated to transforming cancer treatment by developing a cutting-edge therapeutic vaccine that effectively targets HPV cancers, prevents relapse, and reduces treatment-related complications.💉🩺 💡You can scroll through the photos to read Loma’s reflections. Ditte Boilesen Stephanie Holstein-Rønsbo Lasse Nørregaard Martin Wiinberg Bardenfleth Caroline de Blanck Diego R. Lea Fendler Jens Nielsen Trine Bartholdy Bobby Soni Sanne Brun Jensen Umar Adegoke Matthias Wulf Johanna Roostalu Antonia Zoric Tina Chanruk Larsen, Anders Østerby Mønsted, Katrine Villarreal Villumsen, Lea Kynde, Sigrid Hyldig, Tine Roland Presterud #innovation #lifescience #biotech #funding #entrepreneurship

Orakl Oncology raises €11M in seed funding, led by Singular with support from Bpifrance, to launch AI-powered solutions for precision oncology. Founded in 2023 by Fanny Jaulin, PhD, Diane-Laure Pagès, and Gustave Ronteix, Orakl is tackling the challenge of drug development with innovative AI-driven platforms, O-Predict and O-Validate. These tools aim to transform oncology drug development by predicting patient responses and validating new targets. Stay ahead in the startup world! 🌟 Get a weekly digest of key happenings and insights delivered to your inbox every Monday morning. Don't miss out—subscribe now: https://lnkd.in/eJXZrmEj 🚀 #Oncology #AI #Biotech #Startup

Last quarter was the best fundraising quarter for biotech startups in about two years, hopefully indicating that industry downturn will soon be a thing of the past! Demonstrating this, last week Pathios Therapeutics and Stuart Hughes secured $25M in Series B Financing to advance their unique immunotherapy approach into Clinic 💰 Pathios Therapeutics is a biotech startup whose approach targets the acidic microenvironment. This acidic environment triggers immune cell signaling, via receptors such as GPR65, and ultimately leads to disease progression. Pathios aims to reverse immune alterations by blocking GPR65 signaling which will potentially improve cancer treatment outcomes, especially for patients unresponsive to current therapies. How exciting to see these startups acquiring further funding! 👏 Which companies do you think have the potential to secure funding? #biotech #pathiostherapeutics #immunotherapy #recruiter #researchanddevelopment

Story 2nd : Biotech Women Entrepreneurs In a world where innovation meets determination, enter Zumutor Biologics, a beacon of hope in the realm of immuno-oncology. Led by the visionary Kavitha Iyer Rodrigues, this startup is rewriting the narrative of cancer treatment. Imagine a place where diversity isn't just a buzzword but a cornerstone of progress. Zumutor Biologics has crafted a sanctuary of human antibody libraries, a playground for the curious minds seeking breakthroughs in immunotherapy. With their recent Series A4 funding of $6.2 million, Zumutor Biologics isn't just raising capital; they're raising the stakes in the fight against cancer. Led by Accel, Bharat Innovation Fund, and Siana Capital, this infusion of resources catapults them closer to their mission: making life-saving therapies accessible to thousands. But behind every success story lies a journey of resilience. Kavitha's odyssey from a scientist to a trailblazing CEO is a testament to the power of perseverance. From Biocon to Inbiopro to Theramyt Novobiologics, each venture has been a stepping stone towards her ultimate vision. ZM008, Zumutor's lead product, isn't just another drug; it's a beacon of hope for those battling refractory tumors. With its focus on activating Natural Killer (NK) cells, it aims to convert cold tumors into hotbeds of immune activity. But Zumutor Biologics isn't just about innovation; it's about impact. Their commitment to patient benefit echoes in every decision they make, every molecule they engineer. Their vision extends beyond borders, with global licensing on the horizon. And amidst the accolades and achievements, one thing remains clear: Zumutor Biologics is not just a company; it's a movement. From Biospectrum Entrepreneur of the Year to Women Entrepreneur of the Year, their journey is as much about recognition as it is about revolution.Madhuri Awande Zumutor Biologics Kavitha Iyer Rodrigues #womenfounder #startup #entrepreneur #cancer Visit our website for more such stories: https://lnkd.in/dwVWAA33